Cepheid Receives CE Mark for Xpert® Xpress CoV-2/Flu/RSV plus

Cepheid has received the CE mark for Xpert® Xpress CoV-2/Flu/RSV plus, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and respiratory syncytial virus (RSV) infections from a single patient sample. The new plus version of the test provides a third gene target for SARS-CoV-2 detection to meet the challenge of future viral mutations. Xpert® Xpress CoV-2/Flu/RSV plus is designed for use on any of Cepheid’s over 35,000 GeneXpert^® Systems placed worldwide, with results delivered in approximately 36 minutes.

Multiple variants of the virus that causes COVID-19 have been documented globally during the pandemic. Viruses constantly change through mutation, and new variants of a virus are expected to occur over time. Adding a 3rd gene target to the plus version of Cepheid’s CoV-2/Flu/RSV test delivers broader coverage to mitigate the possible effects of future viral genetic drift.

Read full article on the Xpert® Xpress CoV-2/Flu/RSV plus

“This respiratory season, healthcare providers may encounter a range of viral infections with symptoms that overlap with COVID-19, including Flu A, Flu B, and respiratory syncytial virus. Having a fast and accurate test that is designed to detect current and future variants of the viruses that cause COVID-19 and influenza will become increasingly important. The ability to collect one sample and run a single, highly-sensitive multiplexed test that detects and differentiates all four viruses will provide actionable results to inform better front-line decisions within our healthcare systems.”

_{Dr. David Persing, MD, Ph.D.
Chief Medical and Technology Officer}

Cepheid’s new East Bay Logistics Center located in Fremont will also include the distribution of their Xpert® Xpress CoV-2/Flu/RSV plus among other Xpert® Tests and GeneXpert Testing Systems.